Scarica l'app Stockscreener
13.50
1.05%
0.14
Dopo l'orario di chiusura:
13.57
0.07
+0.52%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Viatris Inc Borsa (VTRS) Ultime notizie
Viatris Insider Sold Shares Worth $283,539, According to a Recent SEC Filing - marketscreener.com
Analysts Are Bullish on Top Healthcare Stocks: Siemens Healthineers AG (SEMHF), Viatris (VTRS) - The Globe and Mail
Top Viatris Executive Makes Notable Move With Insider Stock Sale - TipRanks
Viatris Inc officer Campbell sells $283k in shares - Investing.com
Viatris (VTRS) insider trims stake with 21,350-share open-market sale - Stock Titan
Global cardiovascular leaders convene as Viatris joins ACC26 event in New Orleans - Traders Union
Viatris sets long-term targets ahead of investor event - MSN
[144] Viatris Inc SEC Filing - Stock Titan
Barclays raises Viatris stock price target on pipeline potential - Investing.com
Viatris’ Effexor Approved in Japan for Generalized Anxiety Disorder - Contract Pharma
Barclays Adjusts Viatris Price Target to $17 From $15, Maintains Overweight Rating - marketscreener.com
Viatris Stock: Is VTRS Outperforming the Health Care Sector? - Barchart.com
Viatris Says Japan Regulator Approves Effexor for Generalized Anxiety Disorder in Adults - marketscreener.com
Viatris wins Japan approval for Effexor to treat anxiety disorder - Investing.com
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD) - PR Newswire
Levi & Korsinsky Notifies Shareholders of Viatris Inc.(VTRS) of a Class Action Lawsuit and an Upcoming Deadline - The National Law Review
How (VTRS) Movements Inform Risk Allocation Models - Stock Traders Daily
What are analysts saying about Viatris Inc (VTRS) stock? - MSN
Viatris shares break six-session winning streak - MSN
Will Viatris’ 2030 Capital Return And Growth Blueprint Change Viatris' (VTRS) Narrative - Yahoo Finance
Jefferies Keeps Their Buy Rating on Viatris (VTRS) - The Globe and Mail
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Theravance's Q4 Earnings and Revenues Miss Estimates - TradingView
Viatris: Is It A Credible Turnaround Or Overly Optimistic 2030 Plan? - Seeking Alpha
Will Viatris’ 2030 Capital and R&D Framework Reset the Core Investment Narrative for VTRS? - simplywall.st
VTRS Stock Price, Quote & Chart | VIATRIS INC (NASDAQ:VTRS) - ChartMill
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Viatris sets revenue growth targets through 2030 By Investing.com - Investing.com India
Viatris sets revenue growth targets through 2030 - Investing.com
Viatris : VTRS Investor Event Presentation FINAL (1) - marketscreener.com
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 - PR Newswire
Tranche Update on Viatris Inc.'s Equity Buyback Plan announced on February 28, 2022. - marketscreener.com
Class Action Filed Against Viatris Inc. (VTRS) Seeking Recovery for InvestorsContact Levi & Korsinsky - The National Law Review
UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade - MSN
Analysts optimistic ahead of Viatris' Q4 earnings driven by healthy drug pipeline - MSN
Antiretroviral Therapy Market Critical Analysis with Expert Opinion| Gilead Sciences, Viatris, AbbVie - openPR.com
Viatris, Opus gain as FDA to review label expansion for eyecare drug - MSN
Viatris Inc. stock rises Monday, outperforms market - MSN
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
What Are Analysts Saying About Viatris Inc (VTRS) Stock? - Insider Monkey
Henrietta Lacks family settles lawsuit against Viatris over cell use - WBFF
Assessing Viatris (VTRS) Valuation After Mixed Short And Long Term Share Price Moves - Yahoo Finance
UBS and BofA Lift Price Targets on Viatris (VTRS) - Insider Monkey
Assessing Viatris (VTRS) Valuation After Recent Share Price Pullback - simplywall.st
Viatris sells Biocon Biologics stake for $815 million in cash and equity deal - MSN
Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research - Reuters
Viatris' Mylan Drops Claims Disputing Novo's Patent-Infringement Suit - marketscreener.com
Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst - TipRanks
Novo, Mylan Seek Judgment on Key Wegovy Patent Before Trial - Bloomberg Law News
Viatris resolves case over use of woman’s cancer cells to advance drug research - Seeking Alpha
Viatris Inc. stock outperforms market despite losses on the day - MarketWatch
GoodRx (GDRX) Partners with Viatris for Major Medication Discoun - GuruFocus
2.56%
1.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):